The North America Non Invasive Prenatal Testing (NIPT) Market was valued at USD 3,250 million in 2025 and is projected to reach USD 7,850 million by 2035, progressing at a CAGR of 8.7% from 2024 to 2035. This report analyzes the market growth drivers, key trends, opportunities, and recent developments, alongside comprehensive revenue and regional share data.
The economic impact of tariffs on "North America Non Invasive Prenatal Testing Market".
Market Growth Drivers
Increasing Maternal Age and Awareness: The average maternal age at childbirth in North America is rising, leading to a higher risk of chromosomal abnormalities and greater demand for early genetic screening. Companies such as Illumina, Inc. have benefited from this trend by enhancing their NIPT portfolios, making tests more sensitive and accessible. Increased public awareness, driven through healthcare campaigns and improved genetic counseling, is also accelerating NIPT adoption, as expecting parents now opt more frequently for non-invasive and accurate alternatives to traditional screening methods.
Technological Advancements and Product Launches: Rapid advancements in next-generation sequencing (NGS) technologies have significantly improved the sensitivity and specificity of NIPT, fueling adoption across hospitals and diagnostic centers. Roche Diagnostics introduced innovative cfDNA-based platforms in 2023, providing greater accuracy and faster turnaround times. The continuous launch of improved testing kits and automation solutions by major players such as Natera, Inc. has further propelled market growth and expanded application scope beyond common aneuploidies.
Market Trends
Shift Toward Expanded NIPT Panels: There is a notable trend toward offering expanded NIPT panels that screen for a broader array of chromosomal microdeletions and single-gene disorders alongside common trisomies. For example, Laboratory Corporation of America Holdings (Labcorp) launched an expanded NIPT panel in late 2023, enabling detection of rare genetic conditions in a single test. This trend caters to the increasing demand for comprehensive information among expectant parents and clinicians, driving added value and market differentiation.
Integration of Artificial Intelligence and Machine Learning: Industry leaders are leveraging AI and ML algorithms to enhance data interpretation and reduce false positives and negatives. Illumina, Inc. announced the integration of AI-powered analytics into their NIPT platforms in early 2024, leading to faster and even more accurate results. This digital transformation is also streamlining workflow automation, reducing operational burdens on diagnostic laboratories, and improving test accessibility across diverse population groups.
Market Opportunities
Growing Penetration in Untapped Markets: Significant opportunity exists for further NIPT adoption among Medicaid and rural populations in North America. Companies like Myriad Genetics are working with state health agencies to make NIPT more accessible and affordable, expanding the customer base.
Non-Invasive Oncology Screening Cross-Utilization: Diagnostic firms are exploring potential in leveraging cfDNA testing platforms, originally developed for NIPT, for broader non-invasive oncology screening purposes, unlocking adjacent market opportunities and revenue streams.
North America NIPT Market Revenue (USD Million), 2020-2035
The chart illustrates a robust upward trajectory, with revenue rising from USD 1,340 million in 2020 to USD 3,250 million in 2025 and projected to reach USD 7,850 million by 2035. This consistent double-digit growth highlights escalating demand, improved technology penetration, and expanding public and private reimbursement. Market revenue growth is notably strong between 2025 and 2030, driven by new test approvals and increased awareness, while growth steadies thereafter, indicating maturation of the market. The revenue forecast underscores strong business prospects and signals continued investment in research and development.
North America NIPT Market Share by Region (%), 2025
The pie chart demonstrates that the United States dominates the North America NIPT market in 2025, accounting for approximately 73% of total market share, attributed to superior healthcare infrastructure and higher adoption rates. Canada follows with 21%, benefitting from increased policy support and growing public reimbursement of NIPT. Mexico, while a smaller player at 4%, is witnessing robust market expansion through private healthcare partnerships. Other countries and regions make up the remaining 2%, indicating limited market penetration. These patterns emphasize the importance of regional market adaptation and tailored business strategies.
Recent Developments
In May 2024, Natera, Inc. announced the launch of an AI-enhanced NIPT platform designed to detect a broader range of single-gene disorders. This new product leverages machine learning for unparalleled test accuracy, resulting in a significant reduction of false positives. The launch has received overwhelmingly positive feedback from key opinion leaders in maternal-fetal medicine, reinforcing the company’s innovation leadership.
In April 2024, Illumina, Inc. formed a partnership with key U.S. hospital networks to integrate its latest NIPT solutions into routine obstetric screening programs. This collaboration aims to streamline test accessibility and accelerate clinical adoption, particularly among underserved populations. With dedicated funding for awareness campaigns, the partnership is expected to boost adherence to early screening protocols and enhance prenatal care standards.
In March 2024, Roche Diagnostics unveiled a fully automated NIPT system for high-throughput laboratories across North America. This cutting-edge platform features end-to-end workflow automation that significantly reduces turnaround times and operational workload. The system is currently being piloted in several major clinical diagnostic centers, with early results indicating a notable uptick in market share for Roche and improved efficiency for partner labs.
Press Releases